Are Onconeural Antibodies a Clinical Phenomenology in Paraneoplastic Limbic Encephalitis?
Open Access
- 1 January 2013
- journal article
- review article
- Published by Wiley in Mediators of Inflammation
- Vol. 2013, 1-9
Abstract
Paraneoplastic neurological syndromes (PNSs) occur in patients with cancer and can cause clinical symptoms and signs of dysfunction of the nervous system that are not due to a local effect of the tumor or its metastases. Most of these clinical syndromes in adults are associated with lung cancer, especially small cell lung cancer (SCLC), lymphoma, and gynecological tumors. The finding of highly specific antibodies directed against onconeural antigens has revolutionized the diagnosis and promoted the understanding of these syndromes and led to the current hypothesis of an autoimmune pathophysiology. Accumulating data strongly suggested direct pathogenicity of these antibodies. The field of PNS has expanded rapidly in the past few years with the discovery of limbic encephalitis associated with glutamic acid decarboxylase (GAD) 65, the voltage (VGKC-gated potassium channel) complex, the methyl (N-NMDA-D-aspartate), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and gamma aminobutyric acid (GABA) (B) receptors, and so forth. Despite this, the clinical spectrum of these diseases has not yet been fully investigated. The clinical importance of these conditions lies in their frequent response to immunotherapies and, less commonly, their association with distinctive tumors. This review provides an overview on the pathogenesis and diagnosis of PNS, with emphasis on the role of antibodies in limbic encephalitis.Keywords
Funding Information
- National Natural Science Foundation of China (81241147)
This publication has 63 references indexed in Scilit:
- Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitisThe Lancet Neurology, 2011
- Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case seriesThe Lancet Neurology, 2010
- Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotoniaBrain, 2010
- Reversible brain atrophy in anti-NMDA receptor encephalitis: a long-term observational studyJournal of Neurology, 2010
- Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigenThe Lancet Neurology, 2010
- AMPA receptor antibodies in limbic encephalitis alter synaptic receptor locationAnnals of Neurology, 2009
- Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodiesThe Lancet Neurology, 2008
- Paraneoplastic syndromes of the CNSThe Lancet Neurology, 2008
- Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomesJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Course and outcome of acute limbic encephalitis with negative voltage-gated potassium channel antibodiesJournal of Neurology, Neurosurgery & Psychiatry, 2006